Cargando…
Total mesopancreas excision for the treatment of pancreatic head cancer
Mesopancreas is a controversial structure. This study aimed to explore the anatomical characteristics of the mesopancreas, define the range of the total mesopancreas excision (TMpE), and evaluate the feasibility, safety and effectivity of TMpE in the treatment of pancreatic head cancer. The clinical...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687173/ https://www.ncbi.nlm.nih.gov/pubmed/29151943 http://dx.doi.org/10.7150/jca.21341 |
_version_ | 1783278921883582464 |
---|---|
author | Xu, Jingyong Tian, Xiaodong Chen, Yiran Ma, Yongsu Liu, Chang Tian, Long Wang, Jianwei Dong, Jianqiang Cui, Di Wang, Yang Zhang, Weiguang Yang, Yinmo |
author_facet | Xu, Jingyong Tian, Xiaodong Chen, Yiran Ma, Yongsu Liu, Chang Tian, Long Wang, Jianwei Dong, Jianqiang Cui, Di Wang, Yang Zhang, Weiguang Yang, Yinmo |
author_sort | Xu, Jingyong |
collection | PubMed |
description | Mesopancreas is a controversial structure. This study aimed to explore the anatomical characteristics of the mesopancreas, define the range of the total mesopancreas excision (TMpE), and evaluate the feasibility, safety and effectivity of TMpE in the treatment of pancreatic head cancer. The clinical and pathological data of 58 consecutive patients undergoing TMpE for pancreatic head carcinoma from January 2013 to December 2015 were analyzed prospectively. The perioperative morbidity, mortality and clinical outcomes of patients undergoing TMpE were compared with the patients undergoing conventional pancreaticoduodenectomy. The mesopancreas was located in the retropancreatic area, extending from the head, neck, and uncinated process of pancreas to the aorto-caval groove, in which there were loose areolar tissue, adipose tissue, nerve plexus, lymphatic and capillaries. We observed significantly higher R0 rate (94.8% vs. 81.4%, P=0.035), more lymph nodes (16.2 vs. 11.4, P=0.000), lower total and local recurrence rate (half-year local recurrence rate 7.8% vs. 23.7%, P=0.036, one-year 18.2% vs. 39.5%, P=0.018) and longer disease-free survival (16.9 vs. 13.4 months, P=0.044) in TMpE group than in control group. In conclusion, mesopancreas is different from mesorectum because there is no fascial envelop or anatomical boundary in this area. TMpE could be safely and feasibly performed for the treatment of pancreatic head cancer to increase the R0 resection rate and improve the clinical outcomes. |
format | Online Article Text |
id | pubmed-5687173 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-56871732017-11-18 Total mesopancreas excision for the treatment of pancreatic head cancer Xu, Jingyong Tian, Xiaodong Chen, Yiran Ma, Yongsu Liu, Chang Tian, Long Wang, Jianwei Dong, Jianqiang Cui, Di Wang, Yang Zhang, Weiguang Yang, Yinmo J Cancer Research Paper Mesopancreas is a controversial structure. This study aimed to explore the anatomical characteristics of the mesopancreas, define the range of the total mesopancreas excision (TMpE), and evaluate the feasibility, safety and effectivity of TMpE in the treatment of pancreatic head cancer. The clinical and pathological data of 58 consecutive patients undergoing TMpE for pancreatic head carcinoma from January 2013 to December 2015 were analyzed prospectively. The perioperative morbidity, mortality and clinical outcomes of patients undergoing TMpE were compared with the patients undergoing conventional pancreaticoduodenectomy. The mesopancreas was located in the retropancreatic area, extending from the head, neck, and uncinated process of pancreas to the aorto-caval groove, in which there were loose areolar tissue, adipose tissue, nerve plexus, lymphatic and capillaries. We observed significantly higher R0 rate (94.8% vs. 81.4%, P=0.035), more lymph nodes (16.2 vs. 11.4, P=0.000), lower total and local recurrence rate (half-year local recurrence rate 7.8% vs. 23.7%, P=0.036, one-year 18.2% vs. 39.5%, P=0.018) and longer disease-free survival (16.9 vs. 13.4 months, P=0.044) in TMpE group than in control group. In conclusion, mesopancreas is different from mesorectum because there is no fascial envelop or anatomical boundary in this area. TMpE could be safely and feasibly performed for the treatment of pancreatic head cancer to increase the R0 resection rate and improve the clinical outcomes. Ivyspring International Publisher 2017-09-30 /pmc/articles/PMC5687173/ /pubmed/29151943 http://dx.doi.org/10.7150/jca.21341 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Xu, Jingyong Tian, Xiaodong Chen, Yiran Ma, Yongsu Liu, Chang Tian, Long Wang, Jianwei Dong, Jianqiang Cui, Di Wang, Yang Zhang, Weiguang Yang, Yinmo Total mesopancreas excision for the treatment of pancreatic head cancer |
title | Total mesopancreas excision for the treatment of pancreatic head cancer |
title_full | Total mesopancreas excision for the treatment of pancreatic head cancer |
title_fullStr | Total mesopancreas excision for the treatment of pancreatic head cancer |
title_full_unstemmed | Total mesopancreas excision for the treatment of pancreatic head cancer |
title_short | Total mesopancreas excision for the treatment of pancreatic head cancer |
title_sort | total mesopancreas excision for the treatment of pancreatic head cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687173/ https://www.ncbi.nlm.nih.gov/pubmed/29151943 http://dx.doi.org/10.7150/jca.21341 |
work_keys_str_mv | AT xujingyong totalmesopancreasexcisionforthetreatmentofpancreaticheadcancer AT tianxiaodong totalmesopancreasexcisionforthetreatmentofpancreaticheadcancer AT chenyiran totalmesopancreasexcisionforthetreatmentofpancreaticheadcancer AT mayongsu totalmesopancreasexcisionforthetreatmentofpancreaticheadcancer AT liuchang totalmesopancreasexcisionforthetreatmentofpancreaticheadcancer AT tianlong totalmesopancreasexcisionforthetreatmentofpancreaticheadcancer AT wangjianwei totalmesopancreasexcisionforthetreatmentofpancreaticheadcancer AT dongjianqiang totalmesopancreasexcisionforthetreatmentofpancreaticheadcancer AT cuidi totalmesopancreasexcisionforthetreatmentofpancreaticheadcancer AT wangyang totalmesopancreasexcisionforthetreatmentofpancreaticheadcancer AT zhangweiguang totalmesopancreasexcisionforthetreatmentofpancreaticheadcancer AT yangyinmo totalmesopancreasexcisionforthetreatmentofpancreaticheadcancer |